Journals / Anadolu Kliniği Tıp Bilimleri Dergisi / 2020 / Sayı: Special Issue on COVID 19

Chloroquine / Hydroxychloroquine: Pharmacological view of an old drug currently used in COVID-19 treatment

Klorokin/Hidroksiklorokin: COVID-19 tedavisi ile gündeme gelen eski bir ilaca farmakolojik bakış

Pages
204–215
Publication Date
2020-03-20
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although chloroquine / hydroxychloroquine ranks first in the treatment algorithms of COVID-19 disease, more randomized controlled clinical trials are also required.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Drugs that have been proven to be significantly harmless, and whose pharmacokinetics and optimal dosage are well known are subject to re-research for new indications since drug repositioning studies have been accelerated.
📊
Key Findings & Data:Today, clinically proven treatment or vaccine has yet to be established against SARS-CoV-2, which caused the pandemic.
💡
Conclusion & Impact:Although chloroquine / hydroxychloroquine ranks first in the treatment algorithms of COVID-19 disease, more randomized controlled clinical trials are also required.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:SARS-CoV-2 · COVID-19 · klorokin

Abstract

Drugs that have been proven to be significantly harmless, and whose pharmacokinetics and optimal dosage are well known are subject to re-research for new indications since drug repositioning studies have been accelerated. Today, clinically proven treatment or vaccine has yet to be established against SARS-CoV-2, which caused the pandemic. In the treatment of COVID-19 disease, the treatment potential of chloroquine and hydroxychloroquine has drawn considerable attention. In this review, pharmacokinetic and pharmacodynamic properties, the information about use and safety in special populations, and particularly data on efficacy and safety in SARS-CoV-2 infection regarding recent studies of chloroquine/hydroxychloroquine, an old drug that is currently used in the treatment of COVID-19 is presented. Although chloroquine / hydroxychloroquine ranks first in the treatment algorithms of COVID-19 disease, more randomized controlled clinical trials are also required.

Özet

Son yıllarda ilaç yeniden konumlandırma çalışmalarının hız kazanması ile özellikle zararsız olduğu kanıtlanmış, farmakokinetik ve optimal dozu iyi bilinen ilaçlar farklı endikasyonlarda kullanılmak üzere yeniden araştırmalara tabi tutulmaktadır. Günümüzde pandemiye neden olan SARS-CoV-2'ye karşı özellikle klinik olarak etkinliği kanıtlanmış tedavi ya da aşı henüz bulunmamıştır. COVID-19 hastalığının tedavisinde klorokin ve hidroksiklorokinin tedavi potansiyeli büyük ölçüde dikkat çekmiştir. Bu derlemede COVID-19'un tedavisi ile yeniden gündeme gelen eski bir ilaç olan klorokin/hidroksiklorokinin farmakokinetik, farmakodinamik özellikleri, özel popülasyonlardaki kullanımı ve güvenliği ile ilgili mevcut veriler incelenmiş ve literatürdeki güncel araştırmalar doğrultusunda SARS-CoV-2 enfeksiyonundaki etkinlik ve güvenliğine ilişkin veriler sunulmaktadır. Klorokin/Hidroksiklorokinin COVID-19 hastalığının tedavi algoritmalarında ilk sırada yer alması ile birlikte daha fazla randomize kontrollü klinik çalışmanın da gerekli olduğu görülmektedir.

🔖

Cite This Article

BEBİTOĞLU, B. T., OĞUZ, E., HODZİC, A., HATİBOĞLU, N., KAM, Ö. (2020). Chloroquine / Hydroxychloroquine: Pharmacological view of an old drug currently used in COVID-19 treatment. Anadolu Kliniği Tıp Bilimleri Dergisi, Sayı: Special Issue on COVID 19, 204–215. https://ajindex.com/articles/459338

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü COVID-19(SARS-CoV-2 Enfeksiyonu) Rehberi. Bilim Kurulu Çalışması. Ankara; 14 Nisan 2020.
  2. Zhou P, Yang XL, Wang XG et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–73
  3. Wallace DJ. The history of antimalarials. Lupus. 1996;5(1):2–3
  4. Mates M, Nesher G, Zevin S. Quinines—past and present. Harefuah. 2007;146(7): 560–62
  5. Shippey EA, Wagler VD, Collamer AN. Hydroxychloroquine: An old drug with new relevance. Cleve Clin J Med. 2018;85(6):459–67
  6. Stoughton RB. Treatment of chronic lupus erythematosus with atabrine and chloroquine. Ill Med J. 1955;107(6):299–2
  7. Ducharme, J., Farinotti, R. Clinical Pharmacokinetics and Metabolism of Chloroquine. Clin-Pharmacokinet 1996;31:257–74.
  8. Rand JH, Wu XX, Quinn AS et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood. 2008;112(5):1687–95
  9. McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med. 1983;75(1A):11–18
  10. Browning DJ. Pharmacology of Chloroquine and Hydroxychloroquine. In: Hydroxychloroquine and Chloroquine Retinopathy. New York:Springer, 2014; p. 35–63
  11. Tett SE, Cutler D J, Day RO et al. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol. 1989;27(6):771–79
  12. Gustafsson LL, Walker D, Alván G et al. Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol. 1983;15(4):471–79
  13. FDA Approved Drug Products: Hydroxychloroquine Oral Tablet
  14. Collins KP, Jackson KM, Gustafson DL. Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation. J Pharmacol Exp Ther. 2018;365(3):447–59
  15. Munster T, Gibbs JP, Shen D et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46(6):1460–69
  16. Popert AJ. Chloroquine: a review. Rheumatol Rehabil. 1976;15(3):235–38
  17. Laaksonen AL, Koskiahde V, Juva K. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum c